Madrigal Pharmaceuticals logo

Madrigal PharmaceuticalsNASDAQ: MDGL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

06 February 2007

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$6.54 B
-16%vs. 3y high
90%vs. sector
-vs. 3y high
-vs. sector
-98%vs. 3y high
91%vs. sector
-80%vs. 3y high
95%vs. sector

Price

regular market | 7 min ago
$300.02+$5.01(+1.70%)

Dividend

No data over the past 3 years
$62.17 M$92.52 M
$62.17 M-$106.96 M

Analysts recommendations

Institutional Ownership

MDGL Latest News

Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade
zacks.com18 November 2024 Sentiment: -

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
fool.com10 November 2024 Sentiment: POSITIVE

There's a bright future ahead for this company.

Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
zacks.com07 November 2024 Sentiment: POSITIVE

Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
globenewswire.com06 November 2024 Sentiment: POSITIVE

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
seekingalpha.com03 November 2024 Sentiment: POSITIVE

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from Novo Nordisk's Semaglutide poses a market risk, but Rezdiffra's liver-specific mechanism offers a targeted advantage.

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
zacks.com01 November 2024 Sentiment: POSITIVE

MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.

Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
zacks.com31 October 2024 Sentiment: POSITIVE

Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
globenewswire.com30 October 2024 Sentiment: POSITIVE

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego.

Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings
seekingalpha.com28 October 2024 Sentiment: POSITIVE

Madrigal Pharmaceuticals' Rezdiffra, approved for NASH, shows strong early demand and revenue growth, making Q3 earnings a potential catalyst for stock movement. Despite steep Q2 losses, Madrigal's $1.1B cash reserves and strategic execution position Rezdiffra as the market leader in NASH/MASH. Analysts forecast substantial revenue growth and narrowing losses for Madrigal, with expectations of profitability within a few years.

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
globenewswire.com21 October 2024 Sentiment: POSITIVE

CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated NASH cirrhosis has completed enrollment.

What type of business is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The corporation was registered in Delaware in September 2011. The headquarters is located in Pennsylvania. The company's main focus is on the drug MGL-3196 (resmetirom), which has the potential to be used for the treatment of a variety of liver conditions, including non-alcoholic steatohepatitis. Successful further development and final regulatory approval of resmetirom are crucial for the future success of Madrigal Pharmaceuticals, Inc.

What sector is Madrigal Pharmaceuticals in?

Madrigal Pharmaceuticals is in the Healthcare sector

What industry is Madrigal Pharmaceuticals in?

Madrigal Pharmaceuticals is in the Biotechnology industry

What country is Madrigal Pharmaceuticals from?

Madrigal Pharmaceuticals is headquartered in United States

When did Madrigal Pharmaceuticals go public?

Madrigal Pharmaceuticals initial public offering (IPO) was on 06 February 2007

What is Madrigal Pharmaceuticals website?

https://www.madrigalpharma.com

Is Madrigal Pharmaceuticals in the S&P 500?

No, Madrigal Pharmaceuticals is not included in the S&P 500 index

Is Madrigal Pharmaceuticals in the NASDAQ 100?

No, Madrigal Pharmaceuticals is not included in the NASDAQ 100 index

Is Madrigal Pharmaceuticals in the Dow Jones?

No, Madrigal Pharmaceuticals is not included in the Dow Jones index

When was Madrigal Pharmaceuticals the previous earnings report?

No data

When does Madrigal Pharmaceuticals earnings report?

The next expected earnings date for Madrigal Pharmaceuticals is 28 February 2025